These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6966118)

  • 1. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state.
    Magnussen I; Nielsen-Kudsk F
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):257-62. PubMed ID: 6966118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
    Smarius LJ; Jacobs GE; Hoeberechts-Lefrandt DH; de Kam ML; van der Post JP; de Rijk R; van Pelt J; Schoemaker RC; Zitman FG; van Gerven JM; Gijsman HJ
    J Psychopharmacol; 2008 Jun; 22(4):426-33. PubMed ID: 18308795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
    Magnussen I; Jensen TS; Rand JH; Van Woert MH
    Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man.
    Magnussen I; Nielsen-Kudsk F
    Acta Pharmacol Toxicol (Copenh); 1979 Apr; 44(4):308-14. PubMed ID: 311987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man.
    Magnussen I; Engbaek F
    Acta Pharmacol Toxicol (Copenh); 1978 Jul; 43(1):36-42. PubMed ID: 309271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors.
    Magnussen I; Van Woert MH
    Eur J Clin Pharmacol; 1982; 23(1):81-6. PubMed ID: 6182005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
    Thal LJ; Sharpless NS; Wolfson L; Katzman R
    Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carbidopa on the cerebral accumulation of exogenous L-5-hydroxytryptophan in mice.
    Magnussen I
    Acta Pharmacol Toxicol (Copenh); 1984 Sep; 55(3):199-202. PubMed ID: 6334429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of l-5-hydroxytryptophan in healthy subjects.
    Westenberg HG; Gerritsen TW; Meijer BA; van Praag HM
    Psychiatry Res; 1982 Dec; 7(3):373-85. PubMed ID: 6187038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK
    N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manipulation of brain serotonin in the treatment of myoclonus.
    Chadwick D; Jenner P; Harris R; Reynolds EH; Marsden CD
    Lancet; 1975 Sep; 2(7932):434-5. PubMed ID: 51240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency.
    Lado-Abeal J; Graña M; Rey C; Cabezas-Cerrato J
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):203-7. PubMed ID: 9828908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
    Van Woert MH; Sethy VH
    Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
    Growdon JH; Young RR; Shahani BT
    Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral bioavailability of an L-5-HTP/carbidopa tablet].
    Obach R; Pruñonosa J; Vallés J; Vallés JM
    Arch Farmacol Toxicol; 1982 Dec; 8(3):179-82. PubMed ID: 6985117
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.
    Leow KP; Smith MT; Williams B; Cramond T
    Clin Pharmacol Ther; 1992 Nov; 52(5):487-95. PubMed ID: 1424423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
    Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
    J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.